We have shown there is considerable variation in how myositis antibody testing is undertaken and the results obtained for key autoantibody specificities, which may impact on clinical decision-making. Dialogue between manufacturers, diagnostic laboratories and clinicians remains crucial and steps towards harmonisation between laboratories is urgently needed.
Harvey et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: